China’s Clover Biopharma said yesterday a booster shot of its COVID-19 vaccine candidate significantly increased antibody response against the Omicron coronavirus variant from levels seen after two primary shots.
A third dose of its vaccine candidate SCB-2019 resulted in a 19-fold increase in neutralising antibody levels against the Omicron BA.2 subvariant from pre-booster levels, Clover said in a filing to the Hong Kong stock exchange.
The booster shot also elicited a 12-fold rise in the neutralising antibody level against the BA.1 subvariant, the company said, citing preliminary analysis without providing detailed readings.
SCB-2019, which is backed by the Coalition for Epidemic Preparedness Innovation (CEPI), has yet to be approved for commercial use.
Data from a large clinical trial conducted before the spread of Omicron showed SCB-2019 was 67 per cent effective against symptomatic COVID-19 of any degree of severity and 79 per cent against the Delta variant.
Clover did not discuss cell-based responses elicited by the booster, another important part of human immune system different from antibody-based responses.
Clover is also testing a separate candidate SCB-2020S in an early-stage trial and working on a bivalent vaccine candidate targetting variants of concern including Omicron.
Antibody-based readings differ from a vaccine’s efficacy, a rate that reflects how well it could lower the risk of COVID disease or death.
Edits by EP News Bureau
Thank you for your article about (China’s Clover says its COVID booster shot candidate lifts antibody against Omicron) its very help full